The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia

David W. Volk and David A. Lewis

ABSTRACT
Cannabis use has been reported to increase the risk of developing schizophrenia and to worsen symptoms of the illness. Both of these outcomes might be attributable to the disruption by cannabis of the endogenous cannabinoid system's spatiotemporal regulation of the inhibitory circuitry in the prefrontal cortex that is essential for core cognitive processes, such as working memory, which are impaired in schizophrenia. In the healthy brain, the endocannabinoid 2-arachidonylglycerol 1) is synthesized by diacylglycerol lipase in pyramidal neurons; 2) travels retrogradely to nearby inhibitory axon terminals that express the primary type 1 cannabinoid receptor (CB1R); 3) binds to CB1R, which inhibits gamma-aminobutyric acid release from the cholecystokinin-containing population of interneurons; and 4) is metabolized by either monoglyceride lipase, which is located in the inhibitory axon terminal, or by α-β-hydrolase domain 6, which is co-localized presynaptically with diacylglycerol lipase. Investigations of the endogenous cannabinoid system in the prefrontal cortex of subjects with schizophrenia have found evidence of higher metabolism of 2-arachidonylglycerol, as well as both greater CB1R receptor binding and lower levels of CB1R messenger RNA and protein. Current views on the potential pathogenesis of these alterations, including disturbances in the development of the endogenous cannabinoid system, are discussed. In addition, how interactions between these alterations in the endocannabinoid system and those in other inhibitory neurons in the prefrontal cortex in subjects with schizophrenia might increase the liability to adverse outcomes with cannabis use is considered.

Keywords: Cannabinoid, Cannabis, CB1R, Cognitive, Inhibitory, Prefrontal cortex

http://dx.doi.org/10.1016/j.biopsych.2015.06.015

In recent years, cannabis use has increased in prevalence in parallel with an earlier age of onset of cannabis use during adolescence and a greater content of Δ9-tetrahydrocannabinol, the major psychoactive component of cannabis (1). These trends raise the question of whether the higher rates and earlier onset of use of more potent cannabis may lead to potentially deleterious societal health consequences. One area of potential concern arises from evidence of a relationship between cannabis use and schizophrenia.

Schizophrenia is a serious psychiatric illness associated with high levels of disability and morbidity, elevated rates of suicide, and early mortality (2). The disorder is typically characterized by the triad of 1) psychotic symptoms, such as hallucinations and delusions; 2) negative symptoms, such as aloxia and avolition; and 3) impairments in cognitive functions such as working memory and cognitive control. Multiple lines of evidence suggest that cannabis use worsens the course of schizophrenia and may be a risk factor for development of the illness. First, intravenous administration of Δ9-tetrahydrocannabinol has been reported to transiently worsen or induce psychotic symptoms and cognitive deficits in individuals with or without schizophrenia, respectively (3,4). Second, a large number of studies have identified cannabis use as a risk factor for developing schizophrenia (1,5–12). This elevated risk has been reported to remain significant, though may be attenuated, after correcting for confounding variables such as psychotic symptoms preceding cannabis use, familial risk, parental factors, other psychiatric illness, social background, affiliation with deviant peers, socioeconomic status, trauma, baseline IQ, substance use, and level of education (1,5–12). In addition, this risk is inversely related to the age of onset of cannabis use and directly related to the amount of cannabis use. For example, onset of cannabis use at age 15 relative to age 18 was associated with a higher risk of a psychotic disorder at age 26 (6). Third, cannabis use is associated with an earlier age of onset of schizophrenia (13–15), particularly with higher levels of daily cannabis consumption and when the onset of cannabis use begins before age 15 (16,17). Fourth, individuals with schizophrenia who use cannabis have longer durations of hospital stays and more frequent readmissions (18). However, these lines of evidence do not demonstrate that cannabis use is either necessary or sufficient to develop schizophrenia.

Cannabis use in healthy subjects has been reported to result in deficits in the same cognitive domains that are disturbed in schizophrenia and that have the strongest association with poor functioning and long-term outcomes (19–21). For example, otherwise healthy individuals with prolonged...
endocannabinoid signaling in schizophrenia

exposure to high levels of cannabis have performance deficits on neuropsychological tests that persist into periods of abstinence and are more severe in individuals who began using cannabis in adolescence (22). A prospective cohort study found a decline in cognitive function that only occurred in adolescent-onset cannabis users and that did not recover with cessation of cannabis use in adulthood (23). Paradoxically, schizophrenia subjects with a prior history of cannabis use have been reported to have higher performance on multiple cognitive tasks relative to schizophrenia subjects without a cannabis use history (24,25). However, this finding may be explained by the observation that individuals with schizophrenia who have a history of cannabis use have a higher premorbid IQ than those without a history of cannabis use (26). Indeed, higher neurocognitive functioning is also seen in individuals with schizophrenia who abuse other substances (27–29), suggesting that individuals with a more severe course of schizophrenia may lack the cognitive and social capacities to obtain and use illicit substances (27), while a subgroup of schizophrenia subjects with less cognitive impairments may be capable of abusing substances. Alternatively, given the evidence of cannabis use as a risk factor for developing schizophrenia, a subset of individuals at risk for schizophrenia who have relatively normal cognitive functioning may have developed schizophrenia after exposure to cannabis and consequently may have otherwise higher cognitive performance relative to individuals who develop schizophrenia regardless of exposure to cannabis use. However, while epidemiologic studies do not present a fully clear picture of the relationship between cannabis use and cognitive impairments in schizophrenia, direct administration of Δ9-tetrahydrocannabinol to individuals with schizophrenia has been reported to transiently worsen cognitive deficits (4).

Experimental studies in animals have provided more direct evidence of a causal relationship between cannabis use and cognitive impairments. For example, administration of Δ9-tetrahydrocannabinol or other cannabinoid-1 receptor (CB1R) agonists produced cognitive deficits in adolescent, but not adult, rats (30–32). Similarly, regular administration of Δ9-tetrahydrocannabinol to adolescent monkeys altered the trajectory of developmental improvements in spatial working memory (33). These findings suggest that the long-lasting deleterious effects of Δ9-tetrahydrocannabinol on cognitive function may be more prominent when the exposure occurs during periods of neural circuitry development, such as adolescence, which is also the time period when the symptoms of schizophrenia become clinically apparent.

CORTICAL CIRCUITRY AND COGNITIVE PROCESSES IN SCHIZOPHRENIA

Understanding the mechanisms by which cannabis may disrupt the cognitive functions that are also impaired in schizophrenia requires knowledge of aspects of the cortical circuitry that supports cognitive processes such as working memory. For example, spatial working memory, which is altered in adolescent monkeys by persistent exposure to Δ9-tetrahydrocannabinol (33), depends on a distributed neural circuit that includes the dorsolateral prefrontal cortex (DLPFC) (34). In the DLPFC, layer 3 pyramidal neurons provide reciprocal excitatory connections to other layer 3 pyramidal neurons that sustain circuitry activity during the delay period of working memory tasks (35). In addition, the subpopulation of cortical inhibitory (gamma-aminobutyric acid [GABA]) basket neurons that express the calcium-binding protein parvalbumin provide inhibitory input that tunes pyramidal neuron firing (36). The interaction between layer 3 pyramidal neurons and parvalbumin basket neurons generates gamma frequency (30–80 Hz) oscillations whose power scales with the demands of working memory tasks (37,38). In schizophrenia, DLPFC layer 3 pyramidal neurons and parvalbumin basket neurons are altered. For example, the density of dendritic spines, the postsynaptic targets of excitatory inputs from other pyramidal neurons, are lower on layer 3 pyramidal neurons in schizophrenia (39,40). Furthermore, deficits in messenger RNA (mRNA) levels for parvalbumin (41–45) and in parvalbumin protein levels in basket cell axon terminals (46) are present in the DLPFC in schizophrenia. In addition, deficits in mRNA levels for the GABA synthesizing enzyme glutamic acid decarboxylase 67 (GAD67) (47–52) are particularly prominent in parvalbumin neurons (41), and GAD67 protein levels are lower in parvalbumin neuron axon terminals (52). Thus, the connectivity among pyramidal neurons and parvalbumin basket neurons appears to be impaired in the DLPFC in schizophrenia and could contribute to the alterations in gamma oscillations that underlie working memory deficits (53,54).

Active cannabis use may affect cognitive functioning in schizophrenia by further interfering with the regulation of the already dysfunctional interaction between DLPFC pyramidal neurons and parvalbumin basket neurons. For example, in the primate neocortex, the principal receptor for cannabinoids, CB1R, is strongly expressed in the DLPFC (55). In the neocortex, CB1Rs are preferentially localized to the axon terminals of GABA-containing basket neurons that contain the neuropeptide cholecystokinin (CCK) and, to a lesser extent, of some pyramidal neurons (56–58). In fact, the density of CB1Rs is much higher in the axon terminals of CCK basket cells than of pyramidal cells (59–61). The inhibitory axon terminals from CCK basket neurons target both pyramidal neurons and parvalbumin neurons (56,57). Activation of CB1Rs suppresses GABA release from CCK neuron axon terminals onto pyramidal neurons (62), and CCK basket neurons also regulate pyramidal neuron activity (56,63,64). Thus, exogenous cannabinoids such as cannabis broadly suppress CCK neuron-mediated inhibition of pyramidal neurons and parvalbumin neurons without the tightly regulated, spatiotemporal selectivity of endocannabinoids.

THE ENDOCANNABINOID SYSTEM

Further exploration of the relationship between cannabis use, cortical circuitry disturbances, and cognitive impairments in schizophrenia also requires knowledge of the endocannabinoid system. The primary endocannabinoid ligands in the brain include anandamide and 2-arachidonylglycerol (2-AG) (65). Anandamide is a partial CB1R agonist and is found at relatively low concentrations in the brain (65,66). In contrast, 2-AG is a full CB1R agonist and is found at much higher concentrations than anandamide in the brain (67).
Endocannabinoid Signaling in Schizophrenia

Figure 1. Schematic illustration of the endogenous cannabinoid system in the dorsolateral prefrontal cortex (DLPFC) in the healthy state and in schizophrenia. Left: The synthesizing enzyme for the endogenous cannabinoid 2-arachidonoylglycerol (2-AG), diacylglycerol lipase-α (DAGLα), is localized to the dendritic spines of pyramidal neurons. In response to repeated depolarization, 2-AG is synthesized, travels retrogradely, and activates the endogenous cannabinoid-1 receptor (CB1R) (green) in nearby inhibitory axon terminals from cholecystokinin (CCK)-containing basket neurons. 2-AG is then degraded by either monoglyceride lipase (MGL) localized to CCK neuron axon terminals or by the serine hydrolase α-β-hydrolase domain 6 (ABHD6), which is co-localized with DAGLα in the dendritic spines of pyramidal neurons. Right: In schizophrenia, higher messenger RNA (mRNA) levels for ABHD6 (larger font size) have been reported in the DLPFC. Because ABHD6 is co-localized with diacylglycerol lipase in the dendritic spines of DLPFC pyramidal neurons, higher ABHD6 mRNA levels may lead to higher metabolism of 2-AG directly at the source of 2-AG production, which may, in turn, lower 2-AG activity at CB1Rs. In addition, studies have found lower levels of CB1R mRNA (smaller font size) and protein immunoreactivity and higher CB1R binding in the DLPFC of the same schizophrenia subjects. One potential explanation for this apparent discrepancy may be the presence of higher levels of membrane-bound CB1R due to altered trafficking that are accessible to ligand binding, while the total amount of intracellular CB1R is lower.

Physiological and anatomical lines of evidence suggest that 2-AG serves as a retrograde signal from pyramidal neurons to nearby CCK basket neuron axon terminals that contain high concentrations of the CB1R (Figure 1, left panel). In a process known as depolarization-induced suppression of inhibition (DSI), the rapid depolarization of a pyramidal neuron induces short-term depression of GABA release from local CCK neuron axon terminals. Both CB1R and 2-AG are required for DSI. For example, bath application of 2-AG reduces the amplitude of inhibitory postsynaptic currents (68). Furthermore, 2-AG is synthesized by diacylglycerol lipase (DAGL) (67), which has two isoforms. DAGLα is expressed at much higher levels than DAGLβ in adult cortex and is primarily responsible for 2-AG synthesis (69). DAGLα is predominantly localized to pyramidal neurons (58,70–72), and pharmacologic inhibition of DAGL blocks CB1R-mediated DSI (68,73–75).

Once 2-AG has been synthesized and released, it is degraded by monoglyceride lipase (MGL) (76,77) or by α-β-hydrolase domain 6 (ABHD6) (Figure 1, left panel) (78). MGL is localized almost exclusively in presynaptic axon terminals (71,72,79). Consistent with the role of 2-AG in suppressing GABA release, inhibitors of MGL prolong the suppression of inhibitory postsynaptic currents (68,73,80), an effect that is reversible by a CB1R antagonist (68,80). In contrast, inhibitors of fatty acid amide hydrolase, which hydrolyzes anandamide but not 2-AG, have no effect on 2-AG-mediated DSI (68,73,81).

Taken together, these data suggest that MGL is anatomically positioned to inactivate 2-AG at its site of action at CB1R in presynaptic inhibitory axon terminals. In contrast, ABHD6 is co-localized with DAGL in the pyramidal neuron dendritic spines (70,71,78), which allow ABHD6 to regulate 2-AG at its site of production.

In concert, these findings raise the question of whether alterations in the endocannabinoid system in schizophrenia may contribute to, or compensate for, the disturbances in DLPFC circuitry described above. Multiple studies have addressed this question by investigating the status of endocannabinoids and CB1R in the DLPFC in schizophrenia, and we review these studies next. However, it is important to note that the endocannabinoid system is also involved in the regulation of fear and anxiety (82–85) and regulates other neurotransmitter systems in other brain regions, such as glutamatergic signaling in the amygdala (86). Consequently, disturbances in endocannabinoid signaling may also be present in other psychiatric disorders and may have consequences on neurotransmitter function in other brain regions; however, the primary focus of this review article is on endocannabinoid regulation of cortical GABA neuron dysfunction in schizophrenia.

ALTERATIONS IN THE ENDOCANNABINOID SYSTEM IN SCHIZOPHRENIA

The status of endocannabinoid signaling in the DLPFC can first be informed by investigating whether the primary endocannabinoids themselves (i.e., anandamide and 2-AG) are altered in schizophrenia. Initial studies focused on levels of these ligands in the cerebrospinal fluid (CSF) in the illness (Table 1). For example, CSF levels of anandamide were
reported to be eightfold higher in a cohort of 47 first-episode, antipsychotic-naive schizophrenia subjects (87) and a cohort of 27 subjects with prodromal psychotic symptoms (88) relative to healthy subjects. Furthermore, a threefold elevation in blood levels of anandamide were reported in a cohort of 12 subjects in an acute phase of schizophrenia and off antipsychotic medications (89). However, CSF studies have not been able to detect quantifiable levels of 2-AG (90), which is the endocannabinoid present in the highest concentration in the brain (67). Thus, the relationship between levels of endocannabinoids measured in the CSF and peripheral blood and endocannabinoid function in brain parenchyma is not clear. In addition, attempts to quantify 2-AG directly in brain parenchyma in human subjects have also not been successful due to the prominent effect of postmortem delay on 2-AG (91).

The status of endocannabinoid signaling in the DLPFC has been further investigated, though indirectly, by quantifying the synthesizing and metabolizing enzymes for 2-AG (Table 1). In the DLPFC of 42 schizophrenia subjects, mRNA levels for DAGLα, DAGLβ, MGL, or fatty acid amide hydrolase did not differ between schizophrenia and healthy subjects (92) (Figure 1, right panel). However, ABHD6 mRNA levels were elevated in the DLPFC of schizophrenia subjects who were younger (<40 years old) and had a shorter illness duration (<15 years of illness) (93). Because of the co-localization of ABHD6 with DAGL in the dendritic spines of DLPFC pyramidal neurons (70,71,78), higher ABHD6 mRNA levels may lead to higher metabolism of 2-AG directly at the source of 2-AG production in dendritic spines, which may, in turn, lead to lower 2-AG levels and binding at CB1R in the earlier stages of the illness (Figure 1, right panel).

### Table 1. Summary of Key Findings from Studies of Endogenous Cannabinoid Markers in Schizophrenia

<table>
<thead>
<tr>
<th>Source (Reference)</th>
<th>Schizophrenia Cohort</th>
<th>Technique</th>
<th>Finding in Schizophrenia Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cerebrospinal Fluid</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(87)</td>
<td>First-episode, antipsychotic-naive [47]</td>
<td>HPLC/MS</td>
<td>Elevated CSF anandamide levels</td>
</tr>
<tr>
<td>(88)</td>
<td>Prodromal psychosis [27]</td>
<td>HPLC/MS</td>
<td>Elevated CSF anandamide levels</td>
</tr>
<tr>
<td>(90)</td>
<td>[10]</td>
<td>HPLC/MS</td>
<td>Elevated CSF anandamide levels</td>
</tr>
<tr>
<td><strong>Blood</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(89)</td>
<td>Acute symptoms, off antipsychotics [12]</td>
<td>LC-APCI-MS</td>
<td>Elevated blood anandamide levels</td>
</tr>
<tr>
<td><strong>Imaging</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(99)</td>
<td>[9]</td>
<td>PET [11C]-OMAR</td>
<td>Elevated CB1R binding in all brain regions, significant in pons</td>
</tr>
<tr>
<td><strong>Postmortem Brain</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocannabinoid enzymes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(92)</td>
<td>[42]</td>
<td>qPCR</td>
<td>No change in mRNA levels for endocannabinoid synthesizing (DAGL) and metabolizing (MGL, FAAH) enzymes in DLPFC area 9</td>
</tr>
<tr>
<td>(93)</td>
<td>[42]</td>
<td>qPCR</td>
<td>Elevated mRNA levels for 2-AG metabolizing enzyme ABHD6 in DLPFC area 9 of younger subjects; no changes in antipsychotic- or THC-exposed monkeys</td>
</tr>
<tr>
<td>CB1R mRNA and protein</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(101)</td>
<td>[23]</td>
<td>In situ hybridization, immunocytochemistry</td>
<td>Lower CB1R mRNA and protein levels in DLPFC area 9; no change in antipsychotic-exposed monkeys</td>
</tr>
<tr>
<td>(112)</td>
<td>[26]</td>
<td>Immunocytochemistry</td>
<td>Lower CB1R immunoreactivity in DLPFC area 46, no change in depression</td>
</tr>
<tr>
<td>(97)</td>
<td>[37]</td>
<td>qPCR</td>
<td>No change in CB1R mRNA levels in DLPFC area 46</td>
</tr>
<tr>
<td>(104)</td>
<td>[31]</td>
<td>qPCR</td>
<td>No change in CB1R mRNA levels in DLPFC area 9</td>
</tr>
<tr>
<td>CB1R autoradiography</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(94)</td>
<td>[14]</td>
<td>CB1R agonist [3H]-CP55940</td>
<td>Elevated CB1R binding in DLPFC area 9, but not hippocampus, caudate, or putamen</td>
</tr>
<tr>
<td>(97)</td>
<td>[37]</td>
<td>[3H]-CP55940</td>
<td>Elevated CB1R binding in DLPFC area 46 in paranoid subjects</td>
</tr>
<tr>
<td>(98)</td>
<td>[47]</td>
<td>CB1R inverse agonist [3H]-MePPEP</td>
<td>Elevated CB1R binding in DLPFC areas 9 and 46</td>
</tr>
<tr>
<td>(95)</td>
<td>[10]</td>
<td>CB1R antagonist [3H]-SR141716</td>
<td>Elevated CB1R binding in anterior cingulate cortex</td>
</tr>
<tr>
<td>(96)</td>
<td>[8]</td>
<td>[3H]-CP55940</td>
<td>Elevated CB1R binding in superficial layers of posterior cingulate cortex</td>
</tr>
<tr>
<td>(105)</td>
<td>[21]</td>
<td>[3H]-OMAR</td>
<td>Elevated CB1R binding in DLPFC area 9 in same schizophrenia subjects with lower CB1R mRNA and protein levels (101)</td>
</tr>
</tbody>
</table>

2-AG, 2-arachidonoylglycerol; ABHD6, α-β-hydrolase domain 6; CB1R, cannabinoid-1 receptor; CSF, cerebrospinal fluid; DAGL, diacylglycerol lipase; DLPFC, dorsolateral prefrontal cortex; FAAH, fatty acid amide hydrolase; HPLC/MS, high performance liquid chromatography/mass spectrometry; LC-APCI-MS, liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry; MGL, monoglyceride lipase; mRNA, messenger RNA; PET, positron emission tomography; qPCR, quantitative polymerase chain reaction; THC, tetrahydrocannabinol.
Understanding endocannabinoid signaling in the DLPFC in schizophrenia also requires knowledge of the status of the principal receptor, CB1R. Postmortem studies employing receptor autoradiography using radiolabeled CB1R ligands have consistently reported higher CB1R binding in the frontal cortex in schizophrenia (Table 1) (94–98). For example, a study utilizing the CB1R agonist [3H]-CP55940 found higher CB1R binding in DLPFC area 9 in a cohort of 14 schizophrenia subjects relative to healthy subjects (94). Similarly, another study using [3H]-CP55940 found higher levels of CB1R binding in DLPFC area 46 from a cohort of 37 schizophrenia subjects relative to healthy subjects; however, higher CB1R binding was only observed in subjects with paranoid schizophrenia (97). CB1R binding measured using the inverse agonist [3H]-MePPEP was 20% higher in DLPFC areas 9 and 46 in a cohort of 47 schizophrenia subjects (98). In the anterior cingulate cortex, binding of the CB1R antagonist [3H]-SR141716 was 64% higher in a cohort of 10 schizophrenia subjects (95). In posterior cingulate cortex, levels of CB1R binding measured using [3H]-CP55940 were 25% higher in the superficial, but not deeper, cortical layers in a cohort of eight schizophrenia subjects (96). Furthermore, a pilot in vivo positron emission tomography study utilizing the novel CB1R selective ligand [11C]-OMAR found higher brain CB1R binding in a cohort of nine schizophrenia subjects (99) and also an inverse correlation between CB1R binding and negative symptoms in schizophrenia subjects (100).

While these radiolabeled CB1R ligand binding studies have consistently reported higher levels of CB1R binding in schizophrenia, particularly in the DLPFC, studies of CB1R mRNA and protein levels have provided contrasting results (Table 1). For example, a radioimmunocytochemistry study found lower CB1R protein levels in DLPFC area 9 of the right hemisphere in a cohort of 23 schizophrenia subjects relative to healthy subjects (101). This study also reported lower CB1R protein levels using diaminobenzidine-based immunocytochemistry in DLPFC area 9 of the left hemisphere in a subset (n = 12) of the same schizophrenia subjects, suggesting that lower CB1R protein levels are present in both hemispheres of the DLPFC in schizophrenia. This finding appears unlikely to be attributable to a loss of CB1R-expressing neurons, as the total number of neurons has been reported to be unaltered in the frontal cortex in schizophrenia (102). Furthermore, the density of CB1R-immunopositive neurons was also reported to not differ, at least in the anterior cingulate cortex, of 15 schizophrenia subjects relative to subjects with major depressive disorder or bipolar disorder or control subjects (103), although this study did not attempt to quantify CB1R levels. In contrast, two studies of CB1R mRNA levels by quantitative polymerase chain reaction in DLPFC areas 9 or 46 found no differences from comparison subjects in cohorts of 31 and 37 schizophrenia subjects, respectively (97,104). However, a more detailed in situ hybridization study reported an 11% decrease in CB1R mRNA levels that was most prominent in layers 2, 3, 5, and 6 in the same 23 schizophrenia subjects that had lower CB1R protein levels quantified by radioimmunocytochemistry (101). Furthermore, long-term exposure to the typical antipsychotic haloperidol or the atypical antipsychotic olanzapine in monkeys did not affect CB1R mRNA levels quantified by in situ hybridization in the DLPFC (101).

Because almost all studies of CB1R mRNA, protein, and binding levels were not conducted in the same subjects, the reason for the apparent discrepancy in CB1R measures in schizophrenia was not immediately clear. To first address the issue of whether the differences across studies could reflect differences in the cohorts studied, we conducted a receptor binding study using [3H]-OMAR in the same schizophrenia subjects in whom lower CB1R mRNA and protein immunoreactivity levels had been previously reported (Table 1) (105). Schizophrenia subjects with lower CB1R mRNA and protein immunoreactivity levels were found to also have higher levels of [3H]-OMAR binding to CB1R, and [3H]-OMAR receptor binding was negatively correlated with CB1R mRNA levels (105). The surprising combination of lower CB1R mRNA and protein immunoreactivity with higher CB1R binding in the DLPFC of the same schizophrenia subjects suggests at least four different interpretations that can guide further studies that may provide insight into the nature of endocannabinoid system dysfunction in schizophrenia.

First, higher levels of CB1R binding might reflect higher levels of membrane-bound CB1R due to altered trafficking of the receptor (Figure 1, right panel). Indeed, in contrast to most G-protein coupled receptors that are found in the plasma membrane, CB1Rs are largely localized intracellularly (106). Thus, the number of CB1Rs that are accessible to ligand binding at the membrane could be increased in schizophrenia, while the total amount of intracellular CB1R is reduced, as suggested by the findings of lower CB1R mRNA and protein immunoreactivity levels. The recent development of super-resolution microscopy may make it possible to test this hypothesis.

Second, higher levels of CB1R binding might reflect greater receptor affinity. Unfortunately, CB1R affinity has generally not been quantified in schizophrenia. One study reported no differences in CB1R affinity in the DLPFC in schizophrenia but attributed this lack of change in part due to the high levels of assay variance observed in postmortem tissue combined with an insufficient sample size (98). Additional studies that assess CB1R affinity and binding levels in cohorts of schizophrenia subjects that are large enough to detect changes in affinity in the face of high variance are needed to test this interpretation. In addition, although speculative, higher CB1R affinity might be related to higher ABHD6 levels in schizophrenia (93). For example, ABHD6 mRNA and CB1R binding levels were positively correlated in the DLPFC in schizophrenia (93). Because of the co-localization of ABHD6 with DAGL in the dendritic spines of cortical pyramidal neurons (70,71,78), greater expression of ABHD6 mRNA could lead to higher metabolism of 2-AG directly at the source of 2-AG production in dendritic spines, which would, in turn, lower 2-AG activity at CB1Rs (Figure 1, right panel). Lower 2-AG signaling could then lead to a compensatory upregulation in membrane localization through altered trafficking or higher affinity of the affected CB1R in that location. Direct testing of this hypothesis would require animal models that overexpress ABHD6.

Third, the GABA neuron axon terminals that normally express CB1R might not fully develop in schizophrenia, leading to lower overall levels of CB1R mRNA and protein. For example, the normal increase in CB1R immunoreactivity...
across adolescence in the middle layers of primate DLPCF (107) might not occur in schizophrenia, consistent with findings that other markers of DLPCF GABA neurons fit a model of arrested developmental trajectories in schizophrenia (108–110). Thus, it is possible that CB1R affinity in the remaining CB1R-containing axon terminals increases in schizophrenia as a compensatory response to maintain homeostasis of endocannabinoid signaling. Although longitudinal developmental in vivo positron emission tomography imaging studies of CB1R binding in individuals at high risk for schizophrenia are not currently possible, proof-of-concept tests of this hypothesis might be possible in appropriate animal models.

Fourth, higher levels of CB1R binding may reflect higher CB1R levels in excitatory axon terminals (58,111), while CB1R levels are lower in inhibitory axon terminals. The previous radioimmunocytochemistry study that reported lowered CB1R protein levels in schizophrenia (101) utilized a CB1R antibody against an epitope present on inhibitory, but not excitatory, axon terminals (112), while the [3H]-OMAR ligand binds to all available CB1Rs. Thus, studies that quantify CB1R levels specifically in pyramidal neurons in schizophrenia are required to further test this interpretation.

INTERACTIONS BETWEEN ALTERATIONS IN ENDOCANNABINOID AND GABA SIGNALING IN SCHIZOPHRENIA

These alterations in endocannabinoid signaling may have important effects on GABA neuron disturbances in the DLPCF in schizophrenia. For example, as described earlier, the combination of higher levels of ABHD6, and consequently higher 2-AG metabolism and lower 2-AG levels, may lead to a compensatory upregulation of CB1R affinity and/or membrane localization (Figure 1, right panel). This interpretation is supported by the significant correlation between CB1R binding and ABHD6 mRNA in schizophrenia subjects (93), and the net effect of these changes may be to maintain homeostasis of endocannabinoid regulation of GABA signaling. However, the disturbances in GABA neurons could also be upstream to the changes in the endocannabinoid system in schizophrenia. For example, deficits in mRNA levels for the GABA synthesizing enzyme GAD67 are one of the most consistently reported findings in the DLPCF in schizophrenia (47–52). The resulting deficit in GABA synthesis could evoke compensatory changes, such as downregulation of CB1R expression [levels of GAD67 and CB1R mRNAs are positively correlated in the DLPCF in schizophrenia (101)], to preserve GABA signaling strength. The idea that lower GAD67 expression is upstream of lower CB1R expression in schizophrenia is supported by experimental studies. For example, mice with a GAD67 heterozygous null mutation exhibit lower CB1R mRNA levels, without a change in DAGL mRNA levels, in the medial prefrontal cortex (PFC) (113). This pattern of findings is similar to that seen in schizophrenia. In contrast, mice with a CB1R heterozygous or homozygous null mutation had no change in GAD67 mRNA levels in medial PFC (113). Although the alterations in the endocannabinoid and GABA systems in the DLPCF in schizophrenia are correlated, it is possible that both change in response to another disturbance in the illness.

CANNABIS AND THE ENDOCANNABINOID SYSTEM IN SCHIZOPHRENIA

As noted above, individuals with schizophrenia appear to be particularly susceptible to the cognitive-impairing effects of cannabis. For example, under normal physiological conditions, activation of CB1Rs suppresses GABA release only from the CB1R-containing terminals that synapse onto the pyramidal cells whose activity stimulates endocannabinoid signaling. In contrast, cannabis use suppresses GABA release onto pyramidal cells without spatiotemporal selectivity because exogenous cannabinoids affect all CB1R terminals. The adverse consequences of this indiscriminate activation of CB1Rs may be exacerbated in schizophrenia due to the presence of higher membrane-bound levels of CB1R or higher levels of CB1R affinity (94–98,105).

Furthermore, deficits in GABA synthesis due to lower GAD67 mRNA levels in schizophrenia might be partially compensated for by a reduction in endocannabinoid-mediated suppression of GABA release from CB1R-containing axon terminals due to lower 2-AG signaling. Such a compensation could be driven by greater expression of ABHD6 in the early stages of schizophrenia (93). If this hypothesis is true, then the negative effects of cannabis in schizophrenia may occur because exogenous activation of CB1R by cannabis counteracts the compensatory effect of lower 2-AG signaling, at least in the earlier stages of the illness. Consistent with this interpretation, the deleterious effects of cannabis use appear to be most prominent in younger individuals (10,13,14). Interestingly, administration of a CB1R agonist to adolescent but not adult rats impairs the maturation of inhibitory processes in the PFC (114). Taken together, these data suggest the need for preventative strategies directed toward reducing cannabis use in adolescents at risk for schizophrenia, which is especially important given the increasing prevalence of cannabis use, earlier age of onset of cannabis use during adolescence, rising Δ9-tetrahydrocannabinol content of cannabis in recent years, and recent legalization of recreational cannabis use in multiple states (1). Furthermore, the recently announced National Institutes of Health initiative termed Adolescent Brain Cognitive Development will hopefully provide critical insights into the long-term effects of cannabis use on adolescent brain development by prospectively studying the relationship between substance use and cognitive development in thousands of youth.

ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by grants from the National Institutes of Health (MH100066 to Dr. Volk; MH043784 and MH051234 to Dr. Lewis). David A. Lewis currently receives investigator-initiated research support from Pfizer and in 2012–2014 served as a consultant in the areas of target identification and validation and new compound development to Autifony, Bristol-Myers Squibb, Concert Pharmaceuticals, and Sunovion. David W. Volk reports no biomedical financial interests or potential conflicts of interest.

ARTICLE INFORMATION

From the Departments of Psychiatry (DWV, DAL) and Neuroscience (DAL), University of Pittsburgh, Pittsburgh, Pennsylvania.
Endocannabinoid Signaling in Schizophrenia

Address correspondence to David W. Volk, M.D., Ph.D., University of Pittsburgh, Psychiatry, 3811 O’Hara Street, W1655 BST, Pittsburgh, PA 15213; E-mail: volkdv@upmc.edu.

Received Apr 8, 2015; revised Jun 11, 2015; accepted Jun 11, 2015.

REFERENCES


Endocannabinoid Signaling in Schizophrenia


47. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, Jones EG (1995): Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52:258–266.


49. Guidotti A, Auta JM, Davis JM, Gerevini VD, Dwivedi Y, Grayson DR, Freund TF (2000): Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder. Arch Gen Psychiatry 57:1061–1069.


Endocannabinoid Signaling in Schizophrenia